Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab

Table 1 Uveitis response to adalimumab and golimumab

Pat.	Duration of uveitis before GLM (yrs)	Previous therapy	Response to ADA	Con comitant cDMARD	Anti-drug Ab	Response to GLM	Con comitant cDMARD	Anti-drug Ab	Current biologic therapy, response
1	6.2	MTX, ADA	CR, LOR	–	pos	CR	–	neg	GLM
2	4.1	MTX, AZA, ADA	PR, LOR	AZA	neg	PR, LOR	AZA	neg	TFC, PR
3	12.7	MTX, AZA, ETA, SSZ, IFX, MMF, TCR, IFNα, ADA	PR, LOR	–	n.d.	PR	–	n.d.	GLM
4	1.0	MTX, ADA	CR, LOR	MTX	pos	CR	MTX	neg	GLM
5	10.9	MTX, ADA	CR, LOR	–	pos	CR	–	n.d.	GLM
6	17.4	MTX, MMF, ADA	CR, LOR	–	n.d.	CR	–	n.d.	GLM
7	12.3	MTX, ADA	CR, LOR	–	pos	PR, LOR	MTX	n.d.	ADA, CR
8	4.8	MTX, IFX, ADA	PNR	MTX	pos	PNR	MTX	n.d.	TCZ, CR
9	17.3	MTX, AZA, IFX, MMF, ADA	PR, LOR	AZA	n.d.	PR, LOR	MMF	n.d.	ABA, PR
10	2.9	MTX, AZA, IFX, ADA	PNR	MTX	neg	PNR	MTX	n.d.	TCZ, CR

MTX methotrexate, AZA azathioprine, SSZ sulfasalazine, MMF mycophenolatmofetil, TCR tacrolimus, IFNα interferon α, ETA etanercept, IFX infliximab, ADA adalimumab, ABA abatacept, TCZ tocilizumab, TFC tofacitinib, anti-drug-Ab anti-drug-antibodies, CR complete response, PR partial response, PNR primary non-response, LOR loss of response, n.d. not done

ISSN: 1546-0096